Olumiant (baricitinib) is a prescribed treatment for severe alopecia areata in adults. It acts as an immunosuppressant by targeting enzymes that drive inflammation and contribute to hair follicle ...

Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from baseline to week 36. In contrast, the placebo group saw a 9.2% change. The Janus ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- For adults with severe, active, nonsegmental vitiligo, baricitinib combined with narrowband ultraviolet light B (UV-B) is efficacious compared with placebo ...

Baricitinib, a Janus kinase (JAK) inhibitor, combined with narrowband ultraviolet B (UVB) phototherapy, reduced disease activity and improved repigmentation and quality of life in adults with ...

Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study.